Sinovac Biotech, Ltd (SVA)
Sinovac Biotech, Ltd (SVA) is listed on Nasdaq, where it has traded since September 26, 2003.
- Listed On
- Nasdaq
- Listed Since
- September 26, 2003
- Employees
- 2,602
About Sinovac Biotech, Ltd
Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in one segment. It has presence in Chinese Mainland, and Outside Chinese Mainland.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 29 institutions reported holding SVA, with 10.5 million shares worth $224.9 million in aggregate. The largest reported holder was Vivo Capital, with 5.9 million shares worth $38.2 million. Of the 5 largest holders listed below, all 5 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Vivo Capital | 5,903,000 | $38M | Unchanged |
| Orbimed Advisors | 2,718,735 | $184M | Unchanged |
| Renaissance Technologies | 1,312,520 | Unchanged | |
| Neumann Advisory Hong Kong | 315,586 | $2M | Unchanged |
| CalPERS | 68,732 | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is SVA?
Sinovac Biotech, Ltd (SVA) is listed on Nasdaq, where it has traded since September 26, 2003.
Who are the largest institutional holders of SVA?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of SVA were Vivo Capital, Orbimed Advisors and Renaissance Technologies.
How many institutions own SVA?
29 institutions reported a position in SVA for the quarter ended June 30, 2026, worth $224.9 million in total.
Did institutions buy or sell SVA last quarter?
Of the 5 largest reported holders, all 5 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for SVA.
Every reported institutional holder, plus insider and congressional trades in SVA, on SentiSense.